{"@type":"Dataset","integmet_study":"MTBLS3628","mesh_chemical_id":["https://identifiers.org/mesh:C043565","https://identifiers.org/mesh:D019802"],"mesh_chemical_pubtator_kw":["succinyl-adenosine","succinate"],"mesh_disease_id":["https://identifiers.org/mesh:C538191","https://identifiers.org/mesh:D009369","https://identifiers.org/mesh:D002292"],"mesh_disease_pubtator_kw":["FH-deficient tumors","tumors","renal cell carcinoma","tumor","RCC","fumarate hydratase-deficient renal cell carcinoma"],"mesh_gene_id":["https://identifiers.org/ncbigene:2271"],"mesh_gene_pubtator_kw":["FH","fumarate hydratase"],"ncbi_taxonomy_id":["https://identifiers.org/taxonomy:9606"],"ncbi_taxonomy_pubtator_kw":["patients"],"source_id":"https://identifiers.org/metabolights:MTBLS3628","study_findings":"Succinyl-adenosine and succinic-cysteine are biomarkers with >90% predictive value.","study_observation":"Plasma metabolomics in FH-deficient RCC patients.","study_summary":"Biomarkers for FH-deficient renal cell carcinoma identified.","study_title_original":"Distinct succinate modifying products are clinically diagnostic and prognostic biomarkers for fumarate hydratase deficient renal cell carcinoma"}